ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

WSJ BLOG/Health: A.M. Vitals: Health-Care Overhaul Case Ripples Outward

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.) By Mark Long Here's what's making health news this morning: Health Case Ripples Outward (WSJ): After three days of arguments over the constitutionality of the health-care overhaul, it's impossible to predict how the Supreme Court will rule, but skepticism from some justices heightens the possibility it could be overturned in June. Also: Three Days of Hearings Yield Five Take-Aways. Obesity-Linked Cancers Increase (WSJ): Overall cancer diagnoses in the U.S. have dropped, but several cancers linked to obesity and a sedentary lifestyle have risen each year from 1999 through 2008. Cancer: 'Book of Knowledge' Published (BBC): A large "encyclopedia" detailing how hundreds of different cancer cell lines interact with drugs that could speed development of new treatments was published in Nature. In Cancer Science, Many "Discoveries" Don't Hold Up (Reuters): Forty-seven of 53 "landmark" cancer studies from reputable labs couldn't be replicated, the former head of cancer research for Amgen said in a commentary piece in Nature, dimming the prospects for new drug development. FDA Asks Chelsea Therapeutics for More Data on Northera (Dow Jones Newswires): The FDA declined to approve Northera, a low-blood-pressure drug from Chelsea Therapeutics, saying additional data showing efficacy was required. Image source: iStockphoto -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com.

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
07/27/201516:01:00Amgen Announces Webcast of 2015 Second Quarter Financial Results
07/24/201515:21:49Correction to Amgen/Kyprolis Article
07/24/201515:00:06FDA Approves Cholesterol Drug From Regeneron, Sanofi
07/24/201513:30:24FDA Approves Amgen's Kyprolis for Earlier Myeloma Treatment
07/24/201513:25:56FDA Approves Amgen's Kyprolis As a Second-Line Multiple Myeloma...
07/24/201512:40:00FDA Approves Kyprolis® (carfilzomib) For Combination Use In...
07/24/201509:10:04AbbVie's Revenue Growth Misses Expectations
07/24/201508:57:08AbbVie's Revenue Growth Misses Expectations
07/23/201509:00:00Amgen Submits Supplemental New Drug Application For Kyprolis®...
07/22/201509:22:00Biotechnology Sector Stocks Technical Coverage -- Amgen, Exelixis...
07/21/201515:19:03Novartis Can Sell Copycat of Amgen's Neupogen in September, Court...
07/21/201507:08:00European Commission Approves Amgen's New Cholesterol-Lowering...
07/21/201507:02:00European Commission Approves Amgen's New Cholesterol-Lowering...
07/16/201517:27:32Initial Statement of Beneficial Ownership (3)
07/16/201516:01:00Amgen Announces Positive BLINCYTO® (blinatumomab) Phase 2 Study...
07/12/201511:02:03$1.5 Trillion Reasons to Invest in These Companies
07/09/201515:06:03Amgen's Single Most Important FDA Decision of 2015 Is Nearly...
07/06/201507:59:022 Dividend Stocks to Buy in a Market Crash
06/22/201501:03:00Celimmune to Present Experimental Anti-IL-15 Antibody AMG 714...
06/19/201516:00:00Amgen Presents Open-Label Extension Data From Ongoing Phase 2...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad